On February 2, 2016, the Patent Trial and Appeal Board (PTAB) rejected another petition by generic-drug maker Lannett Holdings, which urged the PTAB to review claims of Finnegan client AstraZeneca’s Zomig nasal spray patent. The PTAB denied the petition for inter partes review (IPR) because it was filed too late–more than a year after Lannett was served a district court complaint asserting that the company had infringed the patent. The week prior, the PTAB handed down a similar ruling against Lannett, finding that its IPR petition for another Zomig patent (asserted in the same litigation) was also time-barred.
Commentary
World IP Day: EPO Reveals 33% Jump in Cleantech Inventions Over Five Years
April 26, 2024
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.